Analysis of our cohort of 95 melanoma PDX, several of which were derived from BRAF inhibitor-relapsed tumors, showed that NGFR expression levels were significantly higher in the BRAF inhibitor-resistant melanomas (Fig. 2f). Here, BRAF is linked to melanoma.